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ABSTRACT
MicroRNAs (miRNAs) are short, noncoding RNAs
that regulate gene expression by suppressing mRNA
translation and reducing mRNA stability. A miRNA
can potentially bind many mRNAs, thereby affecting
the expression of oncogenes and tumor suppressor
genes as well as the activity of whole pathways. The
promise of miRNA therapeutics in cancer is to har-
ness this evolutionarily conserved mechanism for
the coordinated regulation of gene expression, and
thus restoring a normal cell phenotype. However, the
promiscuous binding of miRNAs can provoke un-
wanted off-target effects, which are usually caused
by high-dose single-miRNA treatments. Thus, it is
desirable to develop miRNA therapeutics with in-
creased specificity and efficacy. To achieve that, we
propose the concept of miRNA cooperativity in order
to exert synergistic repression on target genes, thus
lowering the required total amount of miRNAs. We
first review miRNA therapies in clinical application.
Next, we summarize the knowledge on the molec-
ular mechanism and biological function of miRNA
cooperativity and discuss its application in cancer
therapies. We then propose and discuss a systems
biology approach to investigate miRNA cooperativity
for the clinical setting. Altogether, we point out the
potential of miRNA cooperativity to reduce off-target
effects and to complement conventional, targeted, or
immune-based therapies for cancer.
MicroRNA THERAPEUTICS IN CANCER
MicroRNAs (miRNAs) are a class of endogenous small
non-coding RNAs, which negatively regulate gene expres-
sion by inducing translational repression or mRNA decay
(1,2). In animals, miRNAs are primarily encoded in the
genome as individual genes or as clusters (3). miRNA bio-
genesis starts with transcription of primary miRNAs that
are processed byDrosha andDicer to generatematuremiR-
NAs. Subsequently, the mature miRNAs are bound by Arg-
onaute protein to form RNA-induced silencing complexes
that can recognize complementary mRNAs to repress tar-
get gene expression (3). Since the discovery of the first
miRNA, the field of miRNA biology has expanded con-
siderably (1,4–6). Because each miRNA regulates the ex-
pression of multiple genes, miRNAs can efficiently regulate
and coordinate multiple cellular pathways and processes,
like the ones involved in cellular growth and proliferation
(6,7). Insights into the roles of miRNAs in the onset, pro-
gression and dissemination of cancers have made them at-
tractive tools and targets for novel therapeutic approaches
(8–10). Dysregulation of miRNAs can contribute to can-
cer establishment and progression, with miRNAs acting as
oncogenes (oncomiRs) (11–13) or tumor suppressors (14–
17). Hence, miRNA-based therapies fall into two differ-
ent approaches: (i) the inhibition of oncomiRs by miRNA
antagonists, such as antisense oligonucleotides, antagomirs
and miRNA sponges, and (ii) augmenting the expression
of tumor suppressor miRNAs using miRNA mimics, like
double-stranded synthetic miRNAs and miRNA expres-
sion vectors. The choice of miRNA therapies depends on
the disease mechanism and on whether the intended out-
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come is the gain or loss of gene function. miRNA an-
tagonists designed with complementary sequences to on-
comiRs prevent them from being loaded into Argonaute
proteins, thereby reducing suppression of their tumor sup-
pressor gene targets (18,19). miRNAmimics are used to re-
store lost or diminished function of tumor suppressor miR-
NAs whose downregulation leads to the activation of onco-
genic pathways (18,20).
Like other RNA therapies, a key obstacle for miRNA
therapeutics is the development of efficient delivery sys-
tems that facilitate safe and effective application (21–23).
As small RNAs are prone to degradation by RNases
in serum or in the endocytic compartment of cells,
two different strategies have been investigated. One is
to alter anti-miRNA oligonucleotides through chemical
modification, yielding locked nucleic acids (LNAs) or a
phosphorothioate-modifiedRNAbackbone(24,25). For ex-
ample, safety, tolerability, pharmacokinetics and poten-
tial efficacy of MRG-106, a LNA-modified antisense in-
hibitor of oncomiR miR-155, is currently tested in an on-
going clinical trial (NCT02580552) for treating patients
with cutaneous T-cell lymphoma. A parallel effort goes
into development of delivery vehicles, such as viral vec-
tors, lipid-based systems and polymeric vectors, to encap-
sulate miRNAs for protection and allow endosomal escape
(24–26). For instance, a lipid-formulated miR-34 mimic
(MRX34) is the first miRNA drug that entered a phase I
trial (NCT01829971) and was later tested in patients with
primary liver cancer or metastatic cancer that has spread
to the liver. In a more recent clinical trial (NCT02369198),
miR-16 mimics packaged by mini-cells were intravenously
administered in patients with mesothelioma or non-small
cell lung cancer (27). Besides cancer, miRNA therapeutics
have also been tested in other diseases like hepatitis C (28)
and type 2 diabetes (29), and some of them have already
succeeded in phase II trials (10). Interestingly, increasing
evidence shows that miRNAs can cooperate to more effi-
ciently regulate the expression of their target genes (42,43).
Since this finding can improve and expand current miRNA-
based therapies, we elaborate on it and discuss its potential
clinical application in the following section.
MicroRNA COOPERATIVITY IN CANCER: MECHA-
NISMS, FUNCTIONS AND POTENTIAL THERAPIES
Although the use of miRNAmimics andmiRNA inhibitors
as therapeutics seems promising, only a small number of
miRNA therapeutics has so far progressed into clinical de-
velopment. One major challenge is the identification of the
best miRNA candidates or miRNA targets for different
types of cancers. An intuitive strategy is to combine gene ex-
pression analysis withmiRNA target prediction algorithms,
such as TargetScan (30). However, this strategy is com-
promised by indirect effects and complex gene regulation
involving different molecular species and their dynamical
interactions. Thus, biochemical techniques based on Arg-
onaute andmiRNA immunoprecipitation (e.g. HITS-CLIP
and PAR-CLIP) have been developed to experimentally
identify miRNA–target interactions at a transcriptome-
wide scale (31). Another challenge for miRNA therapeu-
tics is to avoid or minimize toxicity and off-target effects.
As a single miRNA often represses its targets quite weakly
(21,32), high doses of effective miRNA mimics are usu-
ally required to achieve the expected effect. However, high
doses also provoke undesired consequences, including un-
intended targeting by the administered miRNAs. For ex-
ample, the MRX34 clinical trial had to be terminated due
to immune-related adverse events involving patient deaths.
Such failures may be prevented by lowering the dosage of
the miRNA mimic and consequently reducing off-target
effects, but therapeutic benefits could dwindle equally. To
overcome this problem, a reasonable approach would be
to use lower-dose combinations of miRNAs that synergisti-
cally regulate the expression of a shared target. In this con-
text, we expect a reduction or avoidance of undesired events
in patients when multiple miRNAs are co-administered at
lower levels compared to an individual high-dose miRNA
treatment.
Cooperative and synergistic miRNA regulation is an in-
triguing yet poorly explored mechanism. Different miR-
NAs can for example cooperate by regulating multiple,
complementary targets in a pathway (Figure 1). There are a
few experimentally validated examples where miRNAs ex-
ert synergistic effects in cancer (Table 1). Co-transfection
of miR-34a and miR-15a/16 led to increased cell cycle ar-
rest in non-small cell lung cancer cells due to the fact that
miR-15a and miR-16 specifically downregulate CCNE1
and CCND3. Such gene regulation exerts a complementary
effect to cell-cycle regulation by miR-34a (33). Pencheva
et al. identified that miR-1908, miR-199a-5p and miR-
199a-3p jointly target ApoE signaling in melanoma. LNA-
mediated inhibition of these miRNAs strongly suppressed
melanomametastasis (34). In comparison to single-miRNA
treatment in acute lymphoblastic leukemia cells of chil-
dren, co-expression of miR-125b, miR-100 andmiR-99a re-
sulted in downregulation of multiple targets that is causally
linked to the resistance to the chemotherapeutic agent vin-
cristine (35). Through the investigation of nine miRNA
pairs in glioma cells, Zhao et al. found that extensive syn-
ergy occurred among upregulated miRNAs. They showed
that the highest synergistic effect increasing apoptosis of
glioma cells is achieved through simultaneous inhibition
of miR-20a and miR-21 (36). Derepression of tumor sup-
pressor genes (PDCD4, BTG2 and NEDD4L) by inhibit-
ing miR-21, miR-23a and miR-27a showed synergistic ef-
fects toward reducing pancreatic tumor growth and pro-
gression (37). Furthermore, considering multiple targeting
of miRNAs, researchers proposed miRNAs as adjuvants
in conjunction with available cancer therapies (38). For in-
stance, miRNA modulation can be used to increase the ef-
ficiency of small-molecule inhibitors targeting oncogenes
(39) and to lower effective doses of chemotherapies (40).We
have demonstrated how a potential therapeutic gain can be
achieved by utilizingmiR-205 andmiR-342 as co-adjuvants
to sensitize tumor cells to a genotoxic anti-cancer drug (41).
On the other hand, miRNA cooperativity can be imple-
mented through efficient downregulation of targets com-
mon to multiple miRNAs (Figure 1). Specifically, early
genome-wide studies indicated that miRNAs with bind-
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Figure 1. Implementation of miRNA cooperativity through targeting of a shared pathway or of a shared protein-coding gene. Targeting of several inter-
linked protein-coding genes by multiple miRNAs leads to the regulation of a pathway and thereby modulation of the phenotypic outcome (pathway A).
Concerted targeting of a protein-coding gene by two miRNAs can induce efficient regulation of a biological process that is controlled by the gene (pathway
B). miRNA targets are highlighted in red.
Table 1. Experimentally verified cooperative miRNAs
Target gene
Cooperating
miRNAs Reagents Effect Phenotype Cancer Reference
CCNE1 and
other genes
miR-34a,
miR-15/16
Precursor Synergistic Cell cycle arrest NSCLC (in vitro) (33)
APOE,
DNAJA4
miR-1908,
miR-199a,
miR-199a
Inhibitors Synergistic Metastasis Melanoma (in vitro, in
vivo)
(34)
Multiple genes miR-125b,
miR-100,
miR-99a
Precursor Synergistic Chemoresistance ALL (in vitro) (35)
n/a miR-20a,
miR-21
Inhibitors Synergistic Apoptosis Glioma (in vitro) (36)
PDCD4,
BTG2*,
NEDD4L
miR-21,
miR-23a,
miR-27a
Inhibitors Synergistic Tumor growth PDAC (in vitro, in vivo) (37)
E2F1* miR-205,
miR-342
Mimics Synergistic Chemoresistance Melanoma NSCLC (in
vitro)
(41)
CDKN1A* miR-572,
miR-93
Mimics Synergistic n/a Melanoma (in vitro) (49)
TGFBR2 miR-9,
miR-130b
Mimics Additive n/a NSCLC (in vitro) (50)
DMPK* miR-206,
miR-148a
Precursor Synergistic n/a n/a (51)
RASA1,
SPRED1
miR-21,
miR-206
Mimics Synergistic Apoptosis TNBC (in vitro) (52)
RUNX3 miR-130a,
miR-495
Mimics,
inhibitors
Synergistic Apoptosis Angiogenesis GC (in vitro, in vivo) (53)
PDCD4,
TPM1, RhoC,
HoxD10,
EGFR, MMP2
miR-21,
miR-10b
Inhibitors Synergistic Chemoresistance Tumor
proliferation and invasion
Glioma (in vitro, in
vivo)
(40,100)
The table lists experimentally verified cooperative miRNAs that regulate the expression of a gene or a phenotype in a concerted manner. The genes with
adjacent (13–35 nts) miRNA binding sites are highlighted by asterisks. The regulatory effect is derived from a quantitative analysis of gene or phenotype
regulation by the specified miRNAs. The effect is additive when any amount of one miRNA can be substituted with the same amount of the other miRNA
without increasing or decreasing the effect of the treatment; the effect is synergistic when the combined treatment leads to a significantly stronger effect
than a treatment with the same total amount of either miRNA. The effects of gene regulation by cooperative miRNAs on cell phenotypes are also given
if confirmed in the study, and the category of the experiments (in vitro or in vivo) is specified. Non-small cell lung cancer (NSCLC); acute lymphoblastic
leukemia (ALL); pancreatic ductal adenocarcinoma (PDAC); triple-negative breast cancer (TNBC); gastric cancer (GC); not available (n/a)
ing sites located in close proximity in the 3′ untranslated
region (UTR) of a shared target are more likely to in-
duce stronger gene repression (42–44). Using this crite-
rion, we developed a computational model and published
a database containing thousands of predictions of such co-
operative miRNA pairs (45) (https://triplexrna.org). The
model can be improved by considering the interplay be-
tween mRNAs, miRNA-induced silencing complexes and
RNA-binding proteins that can result in multiple, distinct
mechanisms ofmiRNA cooperation (46,47). It is also worth
noting that endogenous miRNA expression levels and the
abundance of miRNA target sites may impact the magni-
tude of miRNA cooperativity (48).
The notion of cooperative gene regulation by miRNAs
is supported by experimental evidence. We have shown in
melanoma cells that miR-572 and miR-93 cooperatively re-
press CDKN1A protein synthesis during the DNA dam-
age response (49). Using a luciferase reporter system,Mitra
et al. demonstrated that miR-9–5p and miR-130b-3p coop-
eratively regulate TGFBR2 expression by binding to its 3′
UTR (50). Similarly, Koscianska et al. validated the cooper-
ative regulation of DMPK by miR-206 and miR-148a (51).
Furthermore, some studies have demonstrated the potential
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of using antagomirs or mimics of cooperative miRNAs as
cancer therapies. Knockdown of miR-21 and miR-206 re-
stored the expression of their common targets RASA1 and
SPRED1, which inhibit in vivo tumor initiation by suppress-
ing the activity of theRAS-ERK signaling pathway (52). In-
hibition ofmiR-130a andmiR-495 significantly reduced cell
proliferation and angiogenesis in gastric cancer cells both
in vitro and in vivo through the recovery of RUNX3 expres-
sion under hypoxic conditions (53). More recently, we have
demonstrated the cooperative repression of E2F1 by miR-
205 and miR-342 in aggressive melanoma and lung cancer
cell lines, and found that overexpression of both miRNAs
reduced the cells’ chemoresistance (41). Of note, due to the
promiscuous binding of miRNAs, a miRNA can play con-
tradictory roles by targeting different genes (54). Thus, it is
reasonable to speculate that cooperative miRNAs targeting
the same gene or pathway may oppose each other’s direc-
tion of regulation in other circumstances. Consequently, the
action of miRNAs depends on the cellular environment.
Moreover, increasing evidence has indicated that
miRNA-mediated gene regulatory networks are critical for
inferring cooperative miRNA regulation in cancer. The
complexity of such networks results from the multiplicity
of miRNA–target interactions, which often engage in
reciprocal feedback and feedforward loops (55,56). Hence,
network approaches have been applied to infer cooperative
regulation among miRNAs (57,58). Xu et al. identified
cancer-specific cooperative miRNAs using networks that
are reconstructed using miRNA target information, the
biological functions of the miRNA targets and their regu-
latory interactions (59). Li et al. developed an algorithm to
detect synergistic miRNA regulatory modules in ovarian,
breast and thyroid cancers (60). Shao et al. investigated
miRNA cooperativity in pan-cancer networks and identi-
fied similar network structures and expression profiles of
cooperative miRNA pairs for cancers with similar tissue
origins (61).
In addition, it is important to investigate target hubs sub-
ject to coordinated regulation by dozens of miRNAs, as
these are often key regulators of biological processes (62).
We have shown that tight control of CDKN1A expression
by multiple and cooperative miRNAs is important for cell
cycle regulation (49). Similarly, hub miRNAs that target
many genes play a dominant role in regulatory networks
and thus bear potential as prognostic markers and thera-
peutic targets. Yang et al. identified several important hub
miRNAs that are involved in a gene regulatory network in
serous ovarian cancer and demonstrated in vivo the ability of
miR-506 to reduce tumor growth by targeting SNAI2 (63).
Li et al. identified miR-524 and miR-628 as preeminent
regulators of malignant transformation in glioma and also
showed their ability to individually predict the survival of
patients with different glioma grades (64). Su et al. identified
five hubmiRNAs (miR-16–2-3p,miR-890,miR-3201,miR-
602, and miR-877) as potential diagnostic and prognostic
biomarkers for pancreatic ductal adenocarcinoma (65).
Taken together, the above studies demonstrate the power
of combining computational and experimental methods in
advancing our understanding of gene regulation by coop-
erative miRNAs and suggest that miRNA cooperativity
should be considered to enhance efficacy and reduce toxi-
city of miRNA-based therapies for cancer.
A ROAD MAP TOWARD USING SYSTEMS BIOLOGY
APPROACHES TO INVESTIGATE MICRORNA COOP-
ERATIVITY IN ANTI-CANCER THERAPEUTICS
As mentioned before, a challenge in miRNA therapeutics
is the potential toxicity linked to off-target effects. To over-
come this problem, we propose to reduce off-target effects
by using lower doses of cooperative miRNAs that syner-
gistically repress common targets (Figure 2), with candi-
date selection implemented in a systems biology approach.
This approach, combining computational and experimen-
tal methods, has become a staple in advancing our under-
standing of gene regulation by miRNAs (31,56,66–67) and
also holds promise for biomedical application (41,68–69).
We believe thesemethods can be re-purposed and combined
into integrative workflows to exploit miRNA cooperativ-
ity in anti-cancer therapeutics. In particular, we are inter-
ested in miRNA cooperativity that is facilitated by adjacent
miRNA target sites in the human transcriptome (44,45), as
such cooperating miRNAs may exert synergistic effects on
repressing their common targets (42). By definition, the syn-
ergistic action of cooperativemiRNAs requires a lower total
dose to achieve the same degree of repression as a single-
miRNA treatment; yet the actual amounts and ratios for in
vitro or in vivo deployments depend on the specific binding
partners and also on the cellular context.
In the following, we describe an exemplary workflow that
integrates existing methods to systematically identify coop-
erative miRNA pairs targeting cancer genes in the context
of a given metastatic cancer (Figure 3). The workflow con-
sists of five steps: (i) reconstruction of a gene regulatory net-
work containingmolecular species, their interactions as well
as their association to phenotypes and clinical features of
the investigated tumor entity; (ii) extraction of a core reg-
ulatory network that contains key molecules and interac-
tions of biomedical interest; (iii) addition of predicted co-
operating miRNA pairs to the core network; (iv) ranking
of miRNA candidates for therapeutic intervention; and (v)
at last, validation of the identified miRNA candidates using
in vitro and in vivo experiments, with clinical tests and trials
initiated in the case of success. In the following, we describe
and discuss each step of the workflow in detail.
Reconstruction of gene regulatory networks
Information about molecular species and their interactions
related to the tumor entity and the investigated therapeutic
scenario can be collected and curated from the scientific lit-
erature and databases. This information is integrated into a
network in which the nodes account for molecules (e.g. sig-
naling proteins, transcription factors andmiRNAs) and the
edges for their interactions (e.g. activation and inhibition).
Methods, tools and databases for network reconstruction
with an emphasis on miRNAs have been reviewed by oth-
ers (31,70).
In knowledge-driven studies, researchers reconstruct a
gene regulatory network from a few core genes of interest.
For instance, to investigate the role of the E2F1 signaling
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Figure 2. Exploiting miRNA cooperativity in cancer therapeutics. Single-miRNA treatment requires high-dose administration of a specific miRNA to
obtain a desired phenotype. This could lead to unwanted regulation of off-targets and thus to undesired phenotypes. Such effects can be reduced or
avoided by combining miRNAs that jointly repress one gene, which not only reduces the amount of miRNAs required but also decreases off-target effects
and thus the risk of toxicity. The bar plots illustrate the expression profiles of miRNAs (left), on-target genes (middle) and off-target genes (right) in
biological scenarios where single or combined miRNA treatment is applied. Compared to the single treatments (++), the combined miRNA treatment (+)
at lower dose is more efficient in repressing the on-target gene. The experimental design and expected observation are adapted from a study, in which the
synergetic repression of E2F1 using low doses of miR-205 and miR-342 was validated in vitro (41). Due to the reduction of miRNA doses, we also expect
less impact on the off-target genes by the combined miRNA treatment. Bar colors correspond to node colors in the upper diagram.
axis in the context of chemotherapy for melanoma, Vera
et al. reconstructed a network with the core genes E2F1,
p73/DNp73 and miR-205 and expanded it using databases
on transcriptional and post-transcriptional gene regulation
and protein–protein interactions (69). Using the network,
the authors showed that the core genes can regulate the ex-
pression of pro- and anti-apoptotic genes (i.e. Bax, Hrk and
BCL2) through an incoherent feedforward loop. This regu-
lation of apoptotic genes by the signaling axis influences the
sensitivity of tumor cells to genotoxic drugs.
In discovery-driven studies, researchers usually recon-
struct a large network consisting of all genes and their in-
teractions with relevance for the disease. Dreyer et al. devel-
oped a comprehensive network containing signaling path-
ways that are crucial for the development and progression
of cutaneous melanoma and enriched it with melanoma-
associated miRNAs (71). Using the network, the authors
analyzed patient data on responsiveness to immunother-
apy in melanoma and identified a subnetwork linked to
epithelial-to-mesenchymal transition that is regulated by
miR-34a and miR-18a. Sumazin et al. reconstructed an
extensive miRNA-mediated network in glioblastoma, in
which more than 7000 protein-coding genes are regulated
by miRNAs. Follow-up analyses showed that miRNA-
mediated interactions regulate driver genes of tumor ini-
tiation and subtype differentiation and thus may enable
crosstalk between canonical oncogenic pathways underly-
ing glioblastoma (68).
Extraction of core regulatory networks
Due to a large number of participating molecules, their het-
erogeneity and the complex interactions among them, the
behavior of comprehensive regulatory networks is difficult
to simulate and to connect with specific observable disease
outcomes. Thus, we need to modularize the network to un-
derstand general principles that govern the structure and
behavior of a biological system (72). Toward this end, one
can integrate multi-omics and clinical data with network
properties to identify a so-called core regulatory network, a
module that is central in the tumor of interest and also rel-
evant in the therapeutic context. The influence that a core
regulatory network wields is reflected in the properties of
its components. For example, hub genes connect the core
to the rest of the network, while mutation or aberrant ex-
pression of core molecules makes them good candidates for
therapeutic manipulation. Sun et al. reconstructed a com-
prehensive glioblastoma-specific regulatory network com-
posed of miRNAs and transcription factors (73). By filter-
ing the network components using connectivity metrics (i.e.
node degree), the authors obtained a core regulatory net-
work for glioblastoma and identified several miRNAs that
may regulate the disease via the Notch signaling pathway.
Similarly, Sadeghi et al. identified key regulatory interac-
tions responsible for the primary tumor to metastasis tran-
sition in prostate cancer (74). Using a network inference ap-
proach that integrates patient-derived transcriptomic data,
the authors reconstructed a comprehensive regulatory net-
work including protein-coding genes, miRNAs and tran-
scription factors. Key transcription factors and miRNAs
were determined for this network using node degree and be-
tweenness centrality measures whereby an integrative TF-
miRNA regulatory core that drives prostate cancer progres-
sion was identified.
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Figure 3. A systems biology approach to investigate the application of miRNA cooperativity in cancer therapy. The approach feeds biological data of
various sources into computational methods that predict cooperative miRNAs regulating the expression of cancer genes. Experimental validation of the
computational results followed by clinical trials may ultimately lead to the discovery of novel miRNA therapies for cancer.
Integration of miRNA cooperativity information
There are a few computational tools that predict gene reg-
ulation by cooperative miRNAs, ranging from distance-
defined cooperative regulation to structural modeling. The
former predictsmiRNAcooperativity based on the distance
between predicted or validated miRNA binding sites (44).
Structural modeling, on the other hand, predicts coopera-
tive miRNA pairs by simulating molecular interactions of
RNA-induced silencing complexes, miRNAs and mRNA
targets. This approach better resembles the molecular pro-
cesses underlyingmiRNA cooperativity but comes at a high
computational cost (47). The TriplexRNA database com-
bines miRNA target prediction algorithms, sequence and
structural analyses, and kinetic modeling to predict and de-
cipher the synergism that cooperative miRNAs exert on
their targets; it not only increases the precision and accuracy
of distance-based predictions but also makes the genome-
wide identification of cooperative miRNAs computation-
ally affordable (45).
By following the three steps described above, we recon-
structed a network accounting for metastatic melanoma
in the context of anti-PD1 immunotherapy (Figure 4; see
Supplementary Figure S1 and SupplementaryMaterials for
details). Precisely, we made use of availiable comprehen-
sive networks accounting for key pathways in cutaneous
melanoma (71) and for cell-cycle regulation linked to the
emergence of cancer-associated phenotypes (75). We de-
rived a core regulatory network by combining network mo-
tifs, network topology and gene expression profiles that
were measured in melanoma biopsies from patients who re-
ceived anti-PD1 immunotherapy (76). Network motifs are
small structures like feedback and feedforward loops that
are frequently recurring in large networks. These motifs
encode relevant regulatory features and are often deregu-
lated in cancer (56,77–78). Next, we characterized types of
cancer-related genes (i.e. oncogenes and tumor suppressors)
using theUniProtKBdatabase (79) and annotatedmiRNA-
target interactions with experimental validation using miR-
TarBase (80) and starBase (81). We annotated the network
with the hallmarks of cancer that are linked to protein-
coding genes involved in relevant biological functions or
signaling pathways (82). Then, we included miRNA pairs
that cooperate in the regulation of protein-coding genes
in the core network by utilizing the TriplexRNA database
(45). To filter the miRNAs in the core network, we used
datasets that characterize miRNA expression profiles in
three human cell lines (83), namely, one melanocyte cell
line, one melanoma cell line with a weak metastatic phe-
notype (A375), and one with a strong metastatic phenotype
(A2058). By integrating all data, we aimed to identify coop-
erative miRNA pairs that show abnormal expression levels
in melanoma cells, making them potential targets for ma-
nipulating the expression of oncogenic and tumor suppres-
sor genes.
As a result, we obtained a comprehensive network built
from protein–protein interactions, cooperative miRNA-
mediated gene regulation, and hallmarks-of-cancer associ-
ations (Figure 4). This kind of network can be used to visu-
alize andmine high-throughput data generated from in vitro
or in vivo experiments, or from patient-derived samples. For
example, the color of protein-coding genes in Figure 4 in-
dicates their expression levels in melanoma patient groups
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Figure 4. Overview ofmiRNA cooperativity in themelanoma network. The network contains hallmarks of cancer (top layer), protein-coding genes (middle
layer), miRNAs (bottom layer) and their interactions. If a protein-coding gene is connected to two miRNAs (orange lines), it means its mRNA is predicted
to form a triplex with the miRNAs. We show only the triplex with the highest score for a protein-coding gene (Supplementary Table S1). All identified
cooperative miRNAs can be found in Supplementary Table S2 or at www.synmirapy.net. The data used to reconstruct the network can be found in
Supplementary Table S3.
according to their classification into non-responders (NR),
partial responders (PR) and complete responders (CR) to
anti-PD1 therapy in Hugo et al. (76).
Ranking miRNA candidates for therapeutic intervention
While a core regulatory network is less complex, it is en-
riched with potential therapeutic targets and thus allows for
more targeted downstream experimental investigations. Ad-
ditional criteria can be used to select the most promising
candidates for experimental validation, making experimen-
tal validation even more cost-effective in terms of time and
resources. Often knowledge and hypothesis-driven inspec-
tion of computational results (e.g. a table of differentially
expressed miRNAs and their putative targets) is used to se-
lect relevant and promising candidates for experimental val-
idation (84,85). Alternatively, one can combine biological
knowledge, quantitative data and mathematical modeling
to derive a systematic and unbiased ranking of candidate
genes. For instance, Dhawan et al. used a multi-variable lin-
ear model to identify miRNAs common to hallmark gene
signatures across different cancers and ranked the identified
miRNAs based on their strength of association to these sig-
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natures (denoted by the estimated model coefficients) (86).
The analysis prioritized putative associations betweenmiR-
NAs and hallmark phenotypes of cancer. By ranking pu-
tative miRNA binding sites, Mavrakis et al. identified five
miRNAs that can produce cooperative effects on tumor
suppressor genes implicated in the pathogenesis of T-cell
acute lymphoblastic leukemia (87).
In this study, we ranked triplexes formed by target mR-
NAs and the predicted cooperative miRNAs using an equa-
tion that involves the computed equilibrium concentration
and the minimum free energy of the triplexes (see Supple-
mentary Materials for details). We interpret the former as
the likelihood of triplex formation and the latter as the sta-
bility of the triplex. The equation is formulated based on
the assumption that stability is secondary to the likelihood
of triplex formation, and we hypothesized that triplexes
with higher scores are more likely to represent true pos-
itives (Supplementary Table S1). It is also worth noting
that molecular dynamics simulations can be employed to
substantiate the predicted triplexes through analyzing their
structural and thermodynamic properties (41,45). All iden-
tified triplexes for the melanoma network are accessible at
an interactive website, allowing further investigation (www.
synmirapy.net).
Furthermore, we built an interaction network from the
selectedmiRNAs and their targets and enriched it withmul-
tiple layers of information, creating a powerful tool to se-
lect miRNA candidates for experimental validation. More
specifically, we included: (i) the classification of genes as an
oncogene or a tumor suppressor gene; (ii) the association of
protein-coding genes with the hallmarks of cancer; (iii) the
fold-change of protein-coding gene expression levels for the
comparison between non-responders and complete respon-
ders to anti-PD1 treatment from the dataset (76); (iv) the
fold-change ofmiRNAexpression levels for the comparison
between melanoma and melanocyte cell lines; (v) existing
experimental evidence for the miRNA–target interactions;
and (vi) the score for the likelihood of protein-coding genes
to be cooperatively repressed by its targeting miRNAs. The
information visualized and aggregated in the network pro-
vides us with a tool to identify cancer genes whose expres-
sion could be modulated by cooperative miRNAs (Figure 5
and Table 2). In particular, we predicted therapeutic strate-
gies that deploy either miRNA mimics to suppress onco-
genes or miRNA inhibitors to upregulate the expression of
tumor suppressor genes. For instance, we found that the
expression of the oncogene BCL2, which is a regulator of
apoptosis (88), is increased in melanoma patients that do
not respond to anti-PD1 treatment. Both BCL2-targeting
miRNAs (miR-195 and miR-136) are downregulated in
melanoma cells and their abilities to repress BCL2were also
validated at the mRNA and protein levels (miRTarBase en-
try: MIRT006868 and MIRT005362). This suggests that si-
multaneous upregulation of both miRNAs constitutes an
efficient treatment option to repress BCL2. Such a miRNA
treatment might be an alternative to BCL2 antisense ther-
apies for melanoma (89,90). A similar treatment strategy
could also be employed for the other identified oncogenes as
their expression is upregulated in non-responding patients
and their cooperative miRNA regulators are either simulta-
neously downregulated or differentially modulated (i.e. one
miRNA is upregulated and the other is downregulated; Ta-
ble 2). The tumor suppressor BAX is a pro-apoptotic gene
whose activation leads to the release of cytochrome c and
consequently cell death (91). The data showed that BAX ex-
pression is upregulated in non-responding patients while the
expression of its cooperatingmiRNAs is differentially mod-
ulated (i.e. let-7b is upregulated and miR-128 is downregu-
lated) in tumor cells. Hence, targeting let-7b with a specific
inhibitor might augment the expression level of the tumor
suppressor.
Experimental validation of candidate miRNAs
Ultimately, the computational methods described previ-
ously are utilized to support and accelerate experimental
findings. At the same time, the computationally predicted
cooperative miRNA target interactions have to be validated
by in vitro and in vivo experiments prior to considering their
use in clinical trials. There are numerous examples where
putative miRNA-mediated gene regulation in cancer has
been validated experimentally (92,93). For instance, using
target prediction algorithms, Lal et al. predicted a large
number of candidate target genes for miR-24 that are as-
sociated with cell proliferation. The authors experimentally
confirmed that more than a hundred of the putative targets
are directly downregulated by overexpressed miR-24 and
that miR-24 plays a role in regulating cell-cycle progression
and DNA repair (94). We predicted the cooperative regu-
lation of CDKN1A by miR-572 and miR-93 and validated
that both miRNAs can consistently repress the expression
of CDKN1A after provoked genotoxic stress in melanoma
cells (49).
Previous systems biology-driven studies showed that up-
regulation of E2F1 can undermine the effect of anti-PD1
treatment through negative regulation of apoptosis and
promotion of processes associated to cancer aggressive-
ness, such as epithelial-to-mesenchymal transition (71,75).
Our analysis suggests that abnormal expression of E2F1 in
melanoma may be caused by the loss or downregulation of
miRNAs such as miR-205 and miR-342 (Figure 5). Specif-
ically, the data showed that miR-205 is endogenously ex-
pressed in neither melanocytes nor melanoma cells, while
miR-342 expression is downregulated in melanoma cells.
Thus, one therapeutic strategy complementing the anti-
PD1 immunotherapy could be augmenting the expression
of miR-205 and miR-342 to cooperatively downregulate
E2F1 in malignant melanoma. In this line, we combined
sequence alignment, molecular dynamics simulations, and
kinetic modeling to investigate cooperative miRNAs tar-
geting E2F1 (41). We identified and validated that simul-
taneous upregulation of miR-205 and miR-342 is an ef-
ficient way to achieve E2F1 repression using in vitro ex-
periments. The combined treatment using low doses of
both miRNAs enhanced E2F1 repression significantly and
also increased the tumor cells’ sensitivity to conventional
chemotherapy. Taken together, these results show how com-
putational methods like the ones reviewed and discussed
here can be used to prioritize miRNA candidates for anti-
cancer therapies and also guide experimental validation.
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Figure 5. Predictive miRNA treatments for melanoma. The network shows protein-coding genes (PCG; squares) that could be targeted by cooperative
miRNAs (diamonds) for therapy based on their expression profiles in the context of melanoma. The associations between protein-coding genes and cancer
hallmarks are denoted by colors in the ring chart. The gene classification (oncogene or tumor suppressor) is denoted by the color of the square border.
The color of protein-coding gene indicates the fold-change of its expression levels for the comparison between patients undergoing anti-PD1 treatment
(non-responders versus complete responders). Two miRNAs connecting to a protein-coding gene (orange lines) were predicted to form the highest-scoring
triplex with the mRNA of the protein-coding gene. The size of protein-coding genes increases with the score assigned to their triplexes. The color of
the miRNA indicates the fold change of its expression level for the comparison between melanoma cells and human melanocytes (A375 + A2058 versus
control). The thickness of the orange lines is determined by whether or not the putative miRNA–gene interactions have been validated by experiments. The
validation data are from miRTarBase r2018 and starBase v2.0. As direct experiments we consider reporter assays, qRT-PCR and Western blots. Indirect
experiments are high-throughput experiments, such as microarray, RNA sequencing, HITS-CLIP and PAR-CLIP. The data used to visualize the network
can be found in Supplementary Table S4.
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Table 2. Cooperative miRNAs targeting cancer genes
Target gene
Cooperative
miRNAs Direct therapy Role in cancer Reference
MDM2 miR-185-5p* (D)
miR-383-5p* (D)
Small molecule (101) Overexpressed in cancers; Negative
regulator of TP53
(101,102)
ETS1 miR-338-3p* (D)
miR-495-3p* (U)
RNA interference (103) Overexpressed in cancer cells;
Chemoresistance Regulate the
RAS/MAPK pathway
(103–105)
YAP1 let-7g-5p* (D)
miR-424-5p* (U)
Small molecule (106) Activated in a broad number of solid
tumors Involved in tumor initiation,
growth, metastasis and
chemoresistance; Regulate the Hippo
pathway
(106–108)
MYC miR-31-5p (U)
miR-599 (N)
Small molecule (109) Deregulated in more than half of
human cancers; Regulate pathways
underlying cell growth, cell-cycle
progression, metabolism, and survival
(109,110)
BCL2 miR-136-5p# (U)
miR-195-5p# (D)
Small molecule (88)
Oligonucleotides (89) RNA
interference (90)
Regulate mitochondrial integrity,
subsequent caspase activation, and
apoptosis
(17,88–90,111)
PAX3 miR-132-3p* (D)
miR-381-3p (U)
n/a Contribute to cell survival in
melanoma; Drive oncogenic
transformation; Enhance cell invasion
and migration
(112–114)
CCND1 miR-142-3p (N)
miR-494-3p (U)
n/a Sometimes amplified in melanoma
cell-cycle regulator
(115,116)
RARA miR-218-5p* (U)
miR-300 (N)
Natural and synthetic
retinoids (117)
Modulate cell growth and
differentiation in response to
retinoids; Induce chemoresistance
(117–120)
JUN miR-9-5p* (D)
miR-494-3p* (U)
Small molecule (121) Overexpressed in a large fraction of
human melanoma samples; Promote
cell proliferation and tumor
progression; Regulate the MAPK and
JNK/JUN pathway
(121–123)
BAX let-7b-5p (U)
miR-128-3p (D)
Small molecule (17) mRNA
lipofection (124)
Rrg-Gly-Asp-based peptides
(125)
Promote apoptosis; Regulate the
mitochondrial apoptosis pathway
(17,91,111,124,125)
The table lists identified oncogenes (regular font) and one tumor suppressor gene (in italics) that can be targeted by cooperative miRNAs. The texts in
parentheses indicate the regulation ofmiRNAs inmelanoma cells (D: downregulated,U: upregulated,N: non-expressed). The superscripts indicate whether
or not the miRNA–gene interactions have been validated by direct (#) or indirect (*) experiments. The third and fourth columns show available therapies
for the target genes and their known role in cancer, respectively. n/a: not available.
DISCUSSION AND CONCLUSION
Despite the rapid development of miRNA therapeutics for
cancer, there are still concerns related to the effects of
miRNA modulation. These concerns include the lack of
target specificity, the chemical design of anti-miRNA and
miRNA mimics, as well as the efficiency of miRNA deliv-
ery systems to specifically reach tumor cells (25,39). Here,
we discussed a therapeutic strategy that combines two coop-
erative miRNAs to increase efficacy and specificity in gene
regulation, and thus significantly reduce the total dose of
miRNAs needed to achieve a desired effect. Our previous
work showed that cooperative miRNAs used in reduced
doses increase the sensitivity of tumor cells to chemother-
apy through enhanced repression of the intended target
(41). It has also been reported that pooling of small interfer-
ing RNAs (siRNAs) can eliminate off-target effects, which
is achieved by lowering the concentration of individual siR-
NAs (95). Interestingly, siRNAs designed to mimic miRNA
features, with reduced sequence complementarity to their
designated target sites, show improved efficacy and fewer
off-target effects (96). Consequently, one can speculate that
lower doses of multiple miRNAs which act in a coopera-
tive manner may also reduce off-target effects that are the
cause for toxicity in miRNA treatments (97). Of note, it has
been shown that a reduction in off-target effects may not be
achieved when using low-complexity pools of a few siRNAs
(95). Although miRNAs as natural cellular products may
be more efficient than siRNAs in repressing target genes, it
is still required to thoroughly their assess off-target effects
(96).
We proposed a systems biology approach that integrates
computational methods with experiments to identify and
validate cooperative miRNA pairs that can synergistically
modulate the expression of cancer genes and also be used
as therapeutic targets for complementing cancer therapies.
While the approach has been demonstrated to be success-
ful in vitro, it is necessary to expand and upgrade it before
applying newly found miRNA therapies in a clinical set-
ting. This is because miRNA interactions are highly com-
plex since not only mRNAs but also pseudogenes, long
ncRNAs and circular RNAs are among their potential off-
targets. One mechanism whereby these RNAs can interfere
with miRNA function is by miRNA sponging, sequester-
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ing them away from their intended targets (98,99). To pre-
vent titration effects by such decoys, an obvious strategy is
to avoid selecting cooperating miRNAs that have a higher
affinity to bind to competing RNAs than to their intended
targets. This requires expression profiling of RNA competi-
tors and also the analysis of properties of corresponding
miRNA binding sites.
Furthermore, targeted delivery of cooperating miRNAs
is crucial to achieve therapeutic effects. However, there is a
lack of means to ensure precise transmission of miRNA-
targeting reagents such as miRNA mimics and inhibitors
(22). Thus, further work is required in the design of vehi-
cles for their efficient delivery in vivo, especially for tissues
where natural uptake of miRNAs is modest and it is nec-
essary to use carriers to transfect miRNA reagents. For in-
stance, one possible strategy is to coat miRNA-containing
particles with ligands, peptides or antibodies that can rec-
ognize and interact with specific receptors expressed on the
surface of tumor cells. Other potential issues, such as how
to ensure an effective and sufficient miRNA dose in the ap-
propriate target cells in order to achieve therapeutic effects,
are also under investigation (24).
Despite many challenges in the clinical application of
miRNAs, we believe that the advancement of computa-
tional models and biotechnology will allow miRNA coop-
erativity to enhance and diversify miRNA therapeutics, and
thus provide additional treatments against cancer.
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